omega-n-methylarginine has been researched along with Neurally Mediated Faint in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Goetz, AM; Kothari, ML; Medow, MS; Stewart, JM; Sutton, R; Visintainer, P | 1 |
Medow, MS; Merchant, S; Stewart, JM; Suggs, M; Sutton, R; Terilli, C; Visintainer, P | 1 |
2 other study(ies) available for omega-n-methylarginine and Neurally Mediated Faint
Article | Year |
---|---|
Nitric oxide synthase inhibition restores orthostatic tolerance in young vasovagal syncope patients.
Topics: Administration, Intravenous; Adolescent; Adult; Age Factors; Arterial Pressure; Arteries; Cardiac Output; Enzyme Inhibitors; Female; Hemodynamics; Humans; Lower Body Negative Pressure; Male; Nitric Oxide Synthase; omega-N-Methylarginine; Syncope, Vasovagal; Time Factors; Treatment Outcome; Vascular Resistance; Vasoconstriction; Young Adult | 2017 |
Postsynaptic α1-Adrenergic Vasoconstriction Is Impaired in Young Patients With Vasovagal Syncope and Is Corrected by Nitric Oxide Synthase Inhibition.
Topics: Adolescent; Adult; Cardiac Output; Enzyme Inhibitors; Female; Heart Rate; Humans; Male; Nitric Oxide Synthase; omega-N-Methylarginine; Phenylephrine; Splanchnic Circulation; Syncope, Vasovagal; Treatment Outcome; Vascular Resistance; Vasoconstriction | 2016 |